These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
308 related articles for article (PubMed ID: 17030738)
1. New pharmacologic horizons in the treatment of Parkinson disease. Bonuccelli U; Del Dotto P Neurology; 2006 Oct; 67(7 Suppl 2):S30-8. PubMed ID: 17030738 [TBL] [Abstract][Full Text] [Related]
2. Novel pharmacological strategies for motor complications in Parkinson's disease. Konitsiotis S Expert Opin Investig Drugs; 2005 Apr; 14(4):377-92. PubMed ID: 15882115 [TBL] [Abstract][Full Text] [Related]
3. Drugs used to treat Parkinson's disease, present status and future directions. Abdel-Salam OM CNS Neurol Disord Drug Targets; 2008 Oct; 7(4):321-42. PubMed ID: 18991661 [TBL] [Abstract][Full Text] [Related]
4. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Chase TN Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164 [TBL] [Abstract][Full Text] [Related]
5. Current and experimental treatments of Parkinson disease: A guide for neuroscientists. Oertel W; Schulz JB J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098 [TBL] [Abstract][Full Text] [Related]
6. Treatment of Parkinson's disease : what's on the horizon? Wu SS; Frucht SJ CNS Drugs; 2005; 19(9):723-43. PubMed ID: 16142989 [TBL] [Abstract][Full Text] [Related]
7. Treatment of motor symptoms in advanced Parkinson's disease: a practical approach. Maranis S; Tsouli S; Konitsiotis S Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1795-807. PubMed ID: 21645577 [TBL] [Abstract][Full Text] [Related]
8. Can adenosine A Kanda T; Jenner P Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S21-S27. PubMed ID: 33349576 [TBL] [Abstract][Full Text] [Related]
9. Etiopathogenesis and treatment of Parkinson's disease. Gallagher DA; Schapira AH Curr Top Med Chem; 2009; 9(10):860-8. PubMed ID: 19754402 [TBL] [Abstract][Full Text] [Related]
10. Dopamine receptor agonists in the treatment of advanced Parkinson's disease. Stocchi F Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S54-7. PubMed ID: 20123558 [TBL] [Abstract][Full Text] [Related]
11. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages]. Pagonabarraga J; RodrÃguez-Oroz MC Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679 [TBL] [Abstract][Full Text] [Related]
12. Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials. Kalia LV; Brotchie JM; Fox SH Mov Disord; 2013 Feb; 28(2):131-44. PubMed ID: 23225267 [TBL] [Abstract][Full Text] [Related]
13. Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease. Morin N; Di Paolo T Int Rev Neurobiol; 2014; 119():151-67. PubMed ID: 25175965 [TBL] [Abstract][Full Text] [Related]
14. Role of dopamine receptor agonists in the treatment of early Parkinson's disease. Bonuccelli U; Del Dotto P; Rascol O Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S44-53. PubMed ID: 20123557 [TBL] [Abstract][Full Text] [Related]
15. Parkinson's Disease: From Pathogenesis to Pharmacogenomics. Cacabelos R Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28273839 [TBL] [Abstract][Full Text] [Related]